Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 5/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23195488 | 0.91 | IGF1R (0.41) | AKT1SGMS2LRRK2POLBTAAR1 | |
| SCHEMBL29831611 | 0.88 | AKT1 (0.48) | AKT1SGMS2LRRK2POLBTAAR1 | |
| SCHEMBL23163764 | 0.83 | KMT2A (0.44) | LRRK2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3929285 | 0.81 | MEN1 (0.52) | AKT1SGMS2LRRK2POLBTAAR1 | |
| SCHEMBL23164294 | 0.79 | CTSV (0.40) | LRRK2TAAR1MEN1KMT2A | |
| SCHEMBL29831007 | 0.78 | PPIA (0.51) | POLBMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL29831765 | 0.74 | IKBKB (0.46) | AKT1SGMS2LRRK2 | |
| SCHEMBL17594985 | 0.74 | MAOB (0.49) | MAPK1ALDH1A1LMNA | |
| SCHEMBL23163765 | 0.74 | MAPK1 (0.49) | SGMS2MEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL21965417 | 0.73 | SGMS2 (0.47) | AKT1SGMS2LRRK2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351556-B2 | Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-07-08 | — | — | US | disclosed |
| US-20220363643-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FD (FR) | 2022-11-17 | — | — | US | disclosed |
| EP-4037770-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363643-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | P2RX3, OPRL1, P2RX6 | AKT1 4107/4885SGMS2 3818/4885LRRK2 2372/4885 |
| US-12351556-B2 | Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain | P2RX3, P2RX6, P2RX4 | AKT1 4168/4885SGMS2 3672/4885LRRK2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.